Nordic Nanovector to Present Preclinical Data Highlighting the Anti-tumour Effect of Humalutin® in Three Lymphoma Models at AACR 2018
Oslo, Norway, 15 March 2018 Nordic Nanovector ASA (OSE: NANO) announces that it will present a poster reporting the anti-tumour effect of Humalutin® (177Lu-conjugated humanized anti-CD37 antibody, 177Lu-NNV003) in preclinical models of non-Hodgkin’s lymphoma (NHL) at the American Association of Cancer Research (AACR) Annual Meeting 2018. The meeting takes place from 14-18 April in Chicago, USA. The preclinical data to be presented, described in an abstract published yesterday (link ),